Pivotal role of augmented αb-crystallin in tumor development induced by deficient TSC1/2 complex

Oncogene

Volumn 33, Issue 34, 2014, Pages 4352-4358

  Wang, F ^a   Chen, X ^a   Li, C ^a   Sun, Q ^b   Chen, Y ^c   Wang, Y ^a   Peng, H ^d   Liu, Z ^a   Chen, R ^a   Liu, K ^e   Yan, H ^c   Ye, B H ^f   Kwiatkowski, D J ^g   Zhang, H ^a  

^a GRADUATE SCHOOL OF PEKING UNION MEDICAL COLLEGE   (China)

^b TIANJIN MEDICAL UNIVERSITY   (China)

^c FUWAI HOSPITAL   (China)

^d SCRIPPS RESEARCH INSTITUTE   (United States)

^e ZHENGZHOU UNIVERSITY   (China)

^f ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^g BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

mTOR; NF B; TSC; tumor; B crystallin

Indexed keywords

ALPHAB CRYSTALLIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; MULTIPROTEIN COMPLEX; PEPTIDES AND PROTEINS; SMALL HEAT SHOCK PROTEIN; TUBERIN; TUBEROUS SCLEROSIS COMPLEX 1; UNCLASSIFIED DRUG;

ARTICLE; CARCINOGENESIS; CELL PROLIFERATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; TUMOR CELL;

RATTUS;

ALPHA-CRYSTALLIN B CHAIN; ANIMALS; APOPTOSIS; CARCINOGENESIS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; FEMALE; HUMANS; KIDNEY NEOPLASMS; LEIOMYOMA; LUNG NEOPLASMS; LYMPHANGIOLEIOMYOMATOSIS; MALE; MICE; MULTIPROTEIN COMPLEXES; NEOPLASM TRANSPLANTATION; NF-KAPPA B; RATS; TOR SERINE-THREONINE KINASES; TUBEROUS SCLEROSIS; TUMOR SUPPRESSOR PROTEINS; UTERINE NEOPLASMS;

EID: 84906939933     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2013.401     Document Type: Article

References (49)

1. Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell 2007; 12: 9-22
2. Hsieh AC, Liu Y, Edlind MP, Ingolia NT, Janes MR, Sher A et al. The translational landscape of mTOR signalling steers cancer initiation and metastasis. Nature 2012; 485: 55-61
3. Ma J, Sun Q, Mi R, Zhang H. Avian influenza A virus H5N1 causes autophagymediated cell death through suppression of mTOR signaling. J Genet Genomics 2011; 38: 533-537
4. Sun Q, Chen X, Ma J, Peng H, Wang F, Zha X et al. Mammalian target of rapamycin up-regulation of pyruvate kinase isoenzyme type M2 is critical for aerobic glycolysis and tumor growth. Proc Natl Acad Sci USA 2011; 108: 4129-4134
5. Kwiatkowski DJ, Zhang H, Bandura JL, Heiberger KM, Glogauer M, el-Hashemite N et al. A mouse model of TSC1 reveals sex-dependent lethality from liver hemangiomas, and up-regulation of p70S6 kinase activity in Tsc1 null cells. Hum Mol Genet 2002; 11: 525-534
6. Potter CJ, Pedraza LG, Xu T. Akt regulates growth by directly phosphorylating Tsc2. Nat Cell Biol 2002; 4: 658-665
7. Inoki K, Li Y, Zhu T, Wu J, Guan KL. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol 2002; 4: 648-657
8. Manning BD, Tee AR, Logsdon MN, Blenis J, Cantley LC. Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. Mol Cell 2002; 10: 151-162
9. Holz MK, Ballif BA, Gygi SP, Blenis J. mTOR and S6K1 mediate assembly of the translation preinitiation complex through dynamic protein interchange and ordered phosphorylation events. Cell 2005; 123: 569-580
10. Loewith R, Jacinto E, Wullschleger S, Lorberg A, Crespo JL, Bonenfant D et al. Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. Mol Cell 2002; 10: 457-468
11. Hara K, Maruki Y, Long X, Yoshino K, Oshiro N, Hidayat S et al. Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell 2002; 110: 177-189
12. Kim DH, Sarbassov DD, Ali SM, King JE, Latek RR, Erdjument-Bromage H et al. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 2002; 110: 163-175
13. Gingras AC, Raught B, Sonenberg N. Regulation of translation initiation by FRAP/ mTOR. Genes Dev 2001; 15: 807-826
14. Sarbassov DD, Ali SM, Kim DH, Guertin DA, Latek RR, Erdjument-Bromage H et al. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol 2004; 14: 1296-1302
15. The European Chromosome 16 Tuberous Sclerosis Consortium. Identification and characterization of the tuberous sclerosis gene on chromosome 16. Cell 1993; 75: 1305-1315
16. Van Slegtenhorst M, De Hoogt R, Hermans C, Nellist M, Janssen B, Verhoef S et al. Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science 1997; 277: 805-808
17. Zhang H, Cicchetti G, Onda H, Koon HB, Asrican K, Bajraszewski N et al. Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR. J Clin Invest 2003; 112: 1223-1233
18. El-Hashemite N, Zhang H, Henske EP, Kwiatkowski DJ. Mutation in TSC2 and activation of mammalian target of rapamycin signalling pathway in renal angiomyolipoma. Lancet 2003; 361: 1348-1349
19. Roach ES, Gomez MR, Northrup H. Tuberous sclerosis complex consensus conference: Revised clinical diagnostic criteria. J Child Neurol 1998; 13: 624-628
20. Carsillo T, Astrinidis A, Henske EP. Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis. Proc Natl Acad Sci USA 2000; 97: 6085-6090
21. Bittmann I, Rolf B, Amann G, Lohrs U. Recurrence of lymphangioleiomyomatosis after single lung transplantation: New insights into pathogenesis. Hum Pathol 2003; 34: 95-98
22. Iwaki T, Tateishi J. Immunohistochemical demonstration of alphaB-crystallin in hamartomas of tuberous sclerosis. Am J Pathol 1991; 139: 1303-1308
23. Kupsky WJ, Frosch M. Tuberous sclerosis variant with production of Rosenthal fibers (alpha B-crystallin). Pediatr Pathol 1993; 13: 869-873
24. Parcellier A, Schmitt E, Brunet M, Hammann A, Solary E, Garrido C. Small heat shock proteins HSP27 and alphaB-crystallin: Cytoprotective and oncogenic functions. Antioxid Redox Signal 2005; 7: 404-413
25. Mao YW, Liu JP, Xiang H, Li DW. Human alphaA-And alphaB-crystallins bind to Bax and Bcl-X(S) to sequester their translocation during staurosporine- induced apoptosis. Cell Death Differ 2004; 11: 512-526
26. Kamradt MC, Lu M, Werner ME, Kwan T, Chen F, Strohecker A et al. The small heat shock protein alpha B-crystallin is a novel inhibitor of TRAIL-induced apoptosis that suppresses the activation of caspase-3. J Biol Chem 2005; 280: 11059-11066
27. Aoyama A, Steiger RH, Frohli E, Schafer R, von Deimling A, Wiestler OD et al. Expression of alpha B-crystallin in human brain tumors. Int J Cancer 1993; 55: 760-764
28. Shi T, Dong F, Liou LS, Duan ZH, Novick AC, DiDonato JA. Differential protein profiling in renal-cell carcinoma. Mol Carcinog 2004; 40: 47-61
29. Sitterding SM, Wiseman WR, Schiller CL, Luan C, Chen F, Moyano JV et al. AlphaBcrystallin: A novel marker of invasive basal-like and metaplastic breast carcinomas. Ann Diagn Pathol 2008; 12: 33-40
30. Young LR, Inoue Y, McCormack FX. Diagnostic potential of serum VEGF-D for lymphangioleiomyomatosis. N Engl J Med 2008; 358: 199-200
31. Howe SR, Gottardis MM, Everitt JI, Goldsworthy TL, Wolf DC, Walker C. Rodent model of reproductive tract leiomyomata. Establishment and characterization of tumor-derived cell lines. Am J Pathol 1995; 146: 1568-1579
32. Yu K, Toral-Barza L, Shi C, Zhang WG, Lucas J, Shor B et al. Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin. Cancer Res 2009; 69: 6232-6240
33. Goncharova EA, Goncharov DA, Li H, Pimtong W, Lu S, Khavin I et al. mTORC2 is required for proliferation and survival of TSC2-null cells. Mol Cell Biol 2011; 31: 2484-2498
34. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 2006; 441: 431-436
35. Ozes ON, Mayo LD, Gustin JA, Pfeffer SR, Pfeffer LM, Donner DB. NF-kappaB activation by tumour necrosis factor requires the Akt serine-Threonine kinase. Nature 1999; 401: 82-85
36. Dan HC, Cooper MJ, Cogswell PC, Duncan JA, Ting JP, Baldwin AS. Akt-dependent regulation of NF-{kappa}B is controlled by mTOR and Raptor in association with IKK. Genes Dev 2008; 22: 1490-1500
37. Ma J, Meng Y, Kwiatkowski DJ, Chen X, Peng H, Sun Q et al. Mammalian target of rapamycin regulates murine and human cell differentiation through STAT3/p63/ Jagged/Notch cascade. J Clin Invest 2010; 120: 103-114
38. Lang SA, Hackl C, Moser C, Fichtner-Feigl S, Koehl GE, Schlitt HJ et al. Implication of RICTOR in the mTOR inhibitor-mediated induction of insulin-like growth factor-I receptor (IGF-IR) and human epidermal growth factor receptor-2 (Her2) expression in gastrointestinal cancer cells. Biochim Biophys Acta 2010; 1803: 435-442
39. Tanaka K, Babic I, Nathanson D, Akhavan D, Guo D, Gini B et al. Oncogenic EGFR signaling activates an mTORC2-NF-kappaB pathway that promotes chemotherapy resistance. Cancer Discov 2011; 1: 524-538
40. Ousman SS, Tomooka BH, Van Noort JM, Wawrousek EF, O'Connor KC, Hafler DA et al. Protective and therapeutic role for alphaB-crystallin in autoimmune demyelination. Nature 2007; 448: 474-479
41. Bhaskar PT, Nogueira V, Patra KC, Jeon SM, Park Y, Robey RB et al. mTORC1 hyperactivity inhibits serum deprivation-induced apoptosis via increased hexokinase II and GLUT1 expression, sustained Mcl-1 expression, and glycogen synthase kinase 3beta inhibition. Mol Cell Biol 2009; 29: 5136-5147
42. Lamb RF, Roy C, Diefenbach TJ, Vinters HV, Johnson MW, Jay DG et al. The TSC1 tumour suppressor hamartin regulates cell adhesion through ERM proteins and the GTPase Rho. Nat Cell Biol 2000; 2: 281-287
43. Astrinidis A, Cash TP, Hunter DS, Walker CL, Chernoff J, Henske EP. Tuberin, the tuberous sclerosis complex 2 tumor suppressor gene product, regulates Rho activation, cell adhesion and migration. Oncogene 2002; 21: 8470-8476
44. Lee L, Sudentas P, Donohue B, Asrican K, Worku A, Walker V et al. Efficacy of a rapamycin analog (CCI-779) and IFN-gamma in tuberous sclerosis mouse models. Genes Chromosomes Cancer 2005; 42: 213-227
45. Bissler JJ, McCormack FX, Young LR, Elwing JM, Chuck G, Leonard JM et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med 2008; 358: 140-151
46. Krueger DA, Care MM, Holland K, Agricola K, Tudor C, Mangeshkar P et al. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med 2010; 363: 1801-1811
47. McCormack FX, Inoue Y, Moss J, Singer LG, Strange C, Nakata K et al. Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl JMed 2011; 364: 1595-1606
48. Hosoi H, Dilling MB, Liu LN, Danks MK, Shikata T, Sekulic A et al. Studies on the mechanism of resistance to rapamycin in human cancer cells. Mol Pharmacol 1998; 54: 815-824
49. Zhang H, Bajraszewski N, Wu E, Wang H, Moseman AP, Dabora SL et al. PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR. J Clin Invest 2007; 117: 730-738